Personalized medicine in kidney transplantation has the potential to improve outcomes and reduce complications. The aim of this study was to investigate the influence of single nucleotide polymorphisms in genes encoding metabolizing enzymes (CYP3A5) and transporters (ABCC2) on clinical outcomes (acute graft failure and/or acute tubular necrosis (ATN)) in kidney transplant recipients (KTR). This was a multicenter, retrospective cohort study where adult KTR who had undergone kidney transplantation between 2020 and 2021 and received tacrolimus-mycophenolate treatment were enrolled in the study. DNA was extracted from collected blood samples using a commercially available kit. CYP3A5*3, ABCC2 -24C>T and ABCC2 3972C>T SNP were determined by polymerase chain reaction. Of the total 39 patients included, nine (23.1%) KTR had an incidence of acute graft failure and/or ATN. A multiple logistic regression showed wildtype ABCC2 -24C>T C allele had a higher risk of developing acute graft rejection and/or ATN compared to the variant allele carriers (adjusted Odd Ratios [aOR]: 27.675, p = 0.038). Recipients who had delayed graft function (aOR: 49.214, p = 0.012) and a history of CMV infection (aOR: 18.097, p = 0.009) were at 49.2 and 18.1-times increased risk for acute graft failure and/or ATN, respectively. The large aOR was inevitable due to the small sample size and required cautious interpretation. This is the first study to determine the effect of the ABCC2 -24C>T genetic polymorphism on clinical outcomes in Malaysian KTR and forms the basis for further work on ABCC2 -24C>T effects in long-term KTR.

1. Ariffin, N.M., Islahudin, F., Kumolosasi, E., & Makmor-Bakry, M. (2019). Effects of MAO-A and CYP450 on primaquine metabolism in healthy volunteers. Parasitology Research, 118(4), 1011–1018. https://doi.org/10.1007/s00436-019-06223-y
2. Bakar, N.S. (2021). Pharmacogenetics of common SNP affecting drug metabolizing enzymes: Comparison of allele frequencies between European and Malaysian/Singaporean. Drug Metabolism and Personalized Therapy, 36(3), 173–181. https://doi.org/10.1515/dmpt-2020-0164
3. Bowman, L. J., & Brennan, D. C. (2008). The role of tacrolimus in renal transplantation. Expert Opinion on Pharmacotherapy, 9(4), 635–643. https://doi.org/10.1517/14656566.9.4.635
4. Bullingham, R. E., Nicholls, A. J., & Kamm, B. R. (1998). Clinical pharmacokinetics of mycophenolate mofetil. Clinical Pharmacokinetics, 34(6), 429–455. https://doi.org/10.2165/00003088-199834060-00002
5. Chaplin, M., Kirkham, J. J., Dwan, K., Sloan, D. J., Davies, G., & Jorgensen, A. L. (2020). Strengthening the reporting of pharmacogenetic studies: Development of the STROPS guideline. PLoS Medicine, 17(9), e1003344. https://doi.org/10.1371/journal.pmed.1003344
6. Charfeddine, K., Zaghden, S., Kharrat, M., Kamoun, K., Jarraya, F., & Hachicha, J. (2005). Infectious complications in kidney transplant recipients: A single-center experience. In Transplantation Proceedings (Vol. 37, No. 6, pp. xx–xx). Elsevier.
7. Chen, L., & Prasad, G. V. R. (2018). CYP3A5 polymorphisms in renal transplant recipients: Influence on tacrolimus treatment. Pharmacogenomics and Personalized Medicine, 11, 23–33. https://doi.org/10.2147/PGPM.S128691
8. Chen, T.-H., Ou, S.-M., & Tarng, D.-C. (2022). Associations of high anti-CMV IgG titer with renal function decline and allograft rejection in kidney transplant patients. Journal of the Chinese Medical Association, 85(2), 183–189. https://doi.org/10.1097/JCMA.0000000000000673
9. Cheung, C.Y., & Tang, S.C.W. (2022). Personalized immunosuppression after kidney transplantation. Nephrology, 27(6), 475–483. https://doi.org/10.1111/nep.14041
10. Damodaran, S., Bullock, B., Ekwenna, O., Nayebpour, M., Koizumi, N., Sindhwani, P., & Ortiz, J. (2021). Risk factors for delayed graft function and their impact on graft outcomes in live donor kidney transplantation. International Urology and Nephrology, 53(3), 439–446. https://doi.org/10.1007/s11255-020-02685-6
11. Fiorentino, M., Pesce, F., Schena, A., Simone, S., Castellano, G., & Gesualdo, L. (2019). Updates on urinary tract infections in kidney transplantation. Journal of Nephrology, 32(5), 751–761. https://doi.org/10.1007/s40620-019-00585-w
12. Fuggle, S. V., Allen, J. E., Johnson, R. J., Collett, D., Mason, P. D., Dudley, C., Rudge, C. J., Bradley, J. A., & Watson, C. J. (2010). Factors affecting graft and patient survival after live donor kidney transplantation in the UK. Transplantation, 89(6), 694–701. https://doi.org/10.1097/TP.0b013e3181c7dc99
13. Grželj, J., Marovt, M., Marko, P. B., Mlinarič-Raščan, I., Gmeiner, T., & Šmid, A. (2021). Polymorphism in gene for ABCC2 transporter predicts methotrexate drug survival in patients with psoriasis. Medicina, 57(10), 1050. https://doi.org/10.3390/medicina57101050
14. Hamzah, S., Teh, L. K., Siew, J. S. K., Ahmad, G., Wong, H. S., Zakaria, Z. A., & Salleh, M. Z. (2013). Pharmacogenotyping of CYP3A5 in predicting dose-adjusted trough levels of tacrolimus among Malaysian kidney-transplant patients. Canadian Journal of Physiology and Pharmacology, 92(1), 50–57. https://doi.org/10.1139/cjpp-2013-0245
15. Hariharan, S., Johnson, C. P., Bresnahan, B. A., Taranto, S. E., McIntosh, M. J., & Stablein, D. (2000). Improved graft survival after renal transplantation in the United States, 1988 to 1996. New England Journal of Medicine, 342(9), 605–612. https://doi.org/10.1056/NEJM200003023420901
16. Hariharan, S., Mcbride, M. A., Cherikh, W. S., Tolleris, C. B., Bresnahan, B. A., & Johnson, C. P. (2002). Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney International, 62(1), 311–318. https://doi.org/10.1046/j.1523-1755.2002.00424.x
17. Herrero, M., Sánchez-Plumed, J., Galiana, M., Bea, S., Marqués, M., & Aliño, S. (2010). Influence of pharmacogenetic polymorphisms in routine immunosuppression therapy after renal transplantation. In Transplantation Proceedings (Vol. 42, No. 8, pp. xx–xx). Elsevier.
18. Hesselink, D. A., Van Hest, R. M., Mathot, R. A., Bonthuis, F., Weimar, W., De Bruin, R. W., & Van Gelder, T. (2005). Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. American Journal of Transplantation, 5(5), 987–994. https://doi.org/10.1111/j.1600-6143.2005.00808.x
19. Jacobson, P. A., Oetting, W. S., Brearley, A. M., Leduc, R., Guan, W., Schladt, D., Matas, A. J., Lamba, V., Julian, B. A., & Mannon, R. B. (2011). Novel polymorphisms associated with tacrolimus trough concentrations: Results from a multicenter kidney transplant consortium. Transplantation, 91(3), 300–308. https://doi.org/10.1097/TP.0b013e31820437f3
20. Joyce, E., Glasner, P., Ranganathan, S., & Swiatecka-Urban, A. (2017). Tubulointerstitial nephritis: Diagnosis, treatment, and monitoring. Pediatric Nephrology, 32(4), 577–587. https://doi.org/10.1007/s00467-016-3389-0
21. Kamdem, L. K., Streit, F., Zanger, U. M., Brockmoller, J., Oellerich, M., Armstrong, V. W., & Wojnowski, L. (2005). Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clinical Chemistry, 51(8), 1374–1381. https://doi.org/10.1373/clinchem.2005.050120
22. Khare, P., Raj, V., Chandra, S., & Agarwal, S. (2014). Quantitative and qualitative assessment of DNA extracted from saliva for its use in forensic identification. Journal of Forensic Dental Sciences, 6(2), 81–85. https://doi.org/10.4103/0975-1475.132332
23. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. (2009). KDIGO clinical practice guideline for the care of kidney transplant recipients. American Journal of Transplantation, 9(Suppl. S3), S1–S157. https://doi.org/10.1111/j.1600-6143.2009.02834.x
24. Kumar, D., Mian, M., Singer, L., & Humar, A. (2017). An interventional study using cell-mediated immunity to personalize therapy for cytomegalovirus infection after transplantation. American Journal of Transplantation, 17(9), 2468–2473. https://doi.org/10.1111/ajt.14272
25. Lloberas, N., Torras, J., Cruzado, J. M., Andreu, F., Oppenheimer, F., Sánchez-Plumed, J., Gentil, M. A., Brunet, M., Ekberg, H., & Grinyó, J. M. (2011). Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients–results of the Pharmacogenomic Substudy within the Symphony Study. Nephrology Dialysis Transplantation, 26(11), 3784–3793. https://doi.org/10.1093/ndt/gfr152
26. Lu, C. Y., Penfield, J. G., Kielar, M. L., Vazquez, M. A., & Jeyarajah, D. R. (1999). Hypothesis: Is renal allograft rejection initiated by the response to injury sustained during the transplant process? Kidney International, 55(6), 2157–2168. https://doi.org/10.1046/j.1523-1755.1999.00494.x
27. Mac Guad, R., Zaharan, N., Chik, Z., Mohamed, Z., Peng, N., & Adnan, W. (2016). Effects of CYP3A5 genetic polymorphism on the pharmacokinetics of tacrolimus in renal transplant recipients. In Transplantation Proceedings (Vol. 48, No. 9, pp. xx–xx). Elsevier.
28. Malik, O., Saleh, S., Suleiman, B., Ashqar, B., Maibam, A., Yaseen, M., Elrefaei, A., Hines, A., Cornea, V., & El-Husseini, A. (2019). Prevalence, risk factors, treatment, and overall impact of BK viremia on kidney transplantation. In Transplantation Proceedings (Vol. 51, No. 6, pp. xx–xx). Elsevier.
29. Meier-Kriesche, H. U., Schold, J. D., Srinivas, T. R., & Kaplan, B. (2004). Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. American Journal of Transplantation, 4(3), 378–383. https://doi.org/10.1111/j.1600-6143.2004.00332.x
30. Miura, M., Satoh, S., Inoue, K., Kagaya, H., Saito, M., Inoue, T., Suzuki, T., & Habuchi, T. (2007). Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. European Journal of Clinical Pharmacology, 63(12), 1161–1169. https://doi.org/10.1007/s00228-007-0382-x
31. Mohd Tahir, N. A., Mohd Saffian, S., Islahudin, F. H., Abdul Gafor, A. H., Othman, H., Abdul Manan, H., & Makmor-Bakry, M. (2020). Effects of CST3 Gene G73A Polymorphism on Cystatin C in a Prospective Multiethnic Cohort Study. Nephron, 144(4), 204–212. https://doi.org/10.1159/000505963
32. Naesens, M., Kuypers, D. R., Verbeke, K., & Vanrenterghem, Y. J. T. (2006). Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation, 82(8), 1074–1084. https://doi.org/10.1097/01.tp.0000235831.05381.60
33. Neale, J., & Smith, A. C. (2015). Cardiovascular risk factors following renal transplant. World Journal of Transplantation, 5(4), 183–195. https://doi.org/10.5500/wjt.v5.i4.183
34. Ness, D., & Olsburgh, J. (2020). UTI in kidney transplant. World Journal of Urology, 38(1), 81–88. https://doi.org/10.1007/s00345-019-02764-1
35. Nett, P. C., Heisey, D. M., Fernandez, L. A., Sollinger, H. W., & Pirsch, J. D. (2004). Association of cytomegalovirus disease and acute rejection with graft loss in kidney transplantation. Transplantation, 78(7), 1036–1041. https://doi.org/10.1097/01.TP.0000135824.23864.7F
36. Notenboom, S., Wouterse, A. C., Peters, B., Kuik, L. H., Heemskerk, S., Russel, F. G., & Masereeuw, R. (2006). Increased apical insertion of the multidrug resistance protein 2 (MRP2/ABCC2) in renal proximal tubules following gentamicin exposure. Journal of Pharmacology and Experimental Therapeutics, 318(3), 1194–1202. https://doi.org/10.1124/jpet.106.104448
37. Ogasawara, K., Chitnis, S. D., Gohh, R. Y., Christians, U., & Akhlaghi, F. (2013). Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients. Clinical Pharmacokinetics, 52(9), 751–762. https://doi.org/10.1007/s40262-013-0068-1
38. Picard, N., Bergan, S., Marquet, P., Van Gelder, T., Wallemacq, P., Hesselink, D. A., & Haufroid, V. (2016). Pharmacogenetic biomarkers predictive of the pharmacokinetics and pharmacodynamics of immunosuppressive drugs. Therapeutic Drug Monitoring, 38(Suppl 1), S57–S69. https://doi.org/10.1097/FTD.0000000000000251
39. Poggio, E. D., Augustine, J. J., Arrigain, S., Brennan, D. C., & Schold, J. D. (2021). Long-term kidney transplant graft survival—Making progress when most needed. American Journal of Transplantation, 21(8), 2824–2832. https://doi.org/10.1111/ajt.16463
40. Ponticelli, C., Reggiani, F., & Moroni, G. (2022). Delayed graft function in kidney transplant: Risk factors, consequences and prevention strategies. Journal of Personalized Medicine, 12(10), 1557. https://doi.org/10.3390/jpm12101557
41. Renaghan, A. D., & Rosner, M. H. (2022). Acute tubular necrosis. Evidence-Based Nephrology, 1, 123–144. https://doi.org/10.1002/9781119702221.ch9
42. Saeki, T., Ueda, K., Tanigawara, Y., Hori, R., & Komano, T. (1993). Human P-glycoprotein transports cyclosporin A and FK506. Journal of Biological Chemistry, 268(9), 6077–6080. https://doi.org/10.1016/S0021-9258(18.53215-6
43. Sattler, M., Guengerich, F. P., Yun, C. H., Christians, U., & Sewing, K. F. (1992). Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metabolism and Disposition, 20(5), 753–761.
44. Severova-Andreevska, G., Danilovska, I., Sikole, A., Popov, Z., & Ivanovski, N. (2019). Hypertension after kidney transplantation: Clinical significance and therapeutical aspects. Open Access Macedonian Journal of Medical Sciences, 7(7), 1241–1245. https://doi.org/10.3889/oamjms.2019.278
45. Shuker, N., Bouamar, R., van Schaik, R. H., Clahsen-van Groningen, M. C., Damman, J., Baan, C. C., van de Wetering, J., Rowshani, A. T., Weimar, W., & van Gelder, T. (2016). A randomized controlled trial comparing the efficacy of Cyp3a5 genotype-based with body-weight-based tacrolimus dosing after living donor kidney transplantation. American Journal of Transplantation, 16(7), 2085–2096. https://doi.org/10.1111/ajt.13691
46. Shuker, N., Bouamar, R., Weimar, W., van Schaik, R. H., van Gelder, T., & Hesselink, D. A. (2012). ATP-binding cassette transporters as pharmacogenetic biomarkers for kidney transplantation. Clinica Chimica Acta, 413(17-18), 1326–1337. https://doi.org/10.1016/j.cca.2012.04.018
47. Tang, J. T., Andrews, L., van Gelder, T., Shi, Y., Van Schaik, R., Wang, L. L., & Hesselink, D. (2016). Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: Recent developments and ethnic considerations. Expert Opinion on Drug Metabolism & Toxicology, 12(5), 555–565. https://doi.org/10.1517/17425255.2016.1170804
48. Tapiawala, S.N., Tinckam, K.J., Cardella, C.J., Schiff, J., Cattran, D.C., Cole, E.H., & Kim, S.J. (2010). Delayed graft function and the risk for death with a functioning graft. Journal of the American Society of Nephrology, 21(1), 153–158. https://doi.org/10.1681/ASN.2009040412
49. Thishya, K., Sreenu, B., Raju, S. B., & Kutala, V. K. (2021). Impact of pharmacogenetic determinants of tacrolimus and mycophenolate on adverse events in renal transplant patients. Current Drug Metabolism, 22(5), 342–352. https://doi.org/10.2174/1389200222666210302091427
50. Vanichanan, J., Udomkarnjananun, S., Avihingsanon, Y., & Jutivorakool, K. (2018). Common viral infections in kidney transplant recipients. Kidney Research and Clinical Practice, 37(4), 323–337. https://doi.org/10.23876/j.krcp.18.0084
51. Wen, L. S. (Ed.). (2018). Renal pharmacy handbook (3rd ed.). Malaysian Pharmaceutical Society.
52. Wen, X., Casey, M. J., Santos, A. H., Hartzema, A., & Womer, K. L. (2016). Comparison of utilization and clinical outcomes for belatacept-and tacrolimus-based immunosuppression in renal transplant recipients. American Journal of Transplantation, 16(11), 3202–3211. https://doi.org/10.1111/ajt.13859
53. Wu, W. K., Famure, O., Li, Y., & Kim, S. J. (2015). Delayed graft function and the risk of acute rejection in the modern era of kidney transplantation. Kidney International, 88(4), 851–858. https://doi.org/10.1038/ki.2015.190